ELCC 2021 | KRYSTAL-1: adagrasib for KRAS-mutant NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, of The Royal Marsden NHS Foundation Trust, London, UK, gives an overview of the Phase I/II KRYSTAL-1 trial (NCT03785249) evaluating adagrasib in patients with advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), who also have a KRASG12C mutation and have previously been treated with chemotherapy and a PD-1/PD-L1 inhibitor. Of 51 evaluable patients with NSCLC, 45% had a partial response to adagrasib and 51% achieved stable disease. In patients who had STK11-comutations there was an overall response rate of 64%. Overall, the study found that adagrasib is tolerable and demonstrated clinical activity in patients with NSCLC and KRASG12C mutations. Prof. Popat also discusses results of the CodeBreak 200 trial (NCT04303780) investigating AMG 510 with docetaxel for NSCLC. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.